ClinicalTrials.gg
RecruitingNCT07521007PURIFY-TIMI 81Updated Nov 5, 2026

A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis

A Phase 2 interventional study of YN001/Placebo 40mg and YN001/Placebo 20mg in Atherosclerosis and Coronary Artery Disease, sponsored by Beijing Inno Medicine Co., Ltd.. Recruiting at 56 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Beijing Inno Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Nov 5, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
456
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 113 studies in Atherosclerosis with a site in China — 36 open to participants now, 48 under way, 11 of them phase 3. Atherosclerosis · China.

Planned enrollment
26th of 79
456 · median 200
Started
2026
with 14 others
Phase 2
6 of 113
4 open now
Primary completion
2027-07
later than 29 of 47 live
Registered
102nd of 113
by date
Lead sponsor
3 of 113
Beijing Inno Medicine Co., Ltd.

Among the 113 studies in Atherosclerosis with a site in China, this one is the 26th largest by planned enrollment of the 79 interventional ones that give a count, is one of 15 that started in 2026, is one of 6 in phase 2, reaches primary completion later than 29 of the 47 other live ones, and was the 102nd registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

36 of the 113 studies in Atherosclerosis with a site in China are open now. Recruiting first, the newest first:

30 more — sign in →

All 36 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies in Atherosclerosis with a site in China, or all of them as a file.
02

Study summary

This study is designed to evaluate the efficacy and safety of intravenously administered YN001 in patients diagnosed with coronary atherosclerosis, who are receiving background therapy for cardiovascular (CV) risk factors management.

Read the detailed description

This is a multinational, multicenter, randomized, parallel, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of intravenously administered YN001 compared with placebo in participants with coronary atherosclerosis who are receiving background therapy for CV risk factors management.

A total of 456 participants are expected to be enrolled. The study will consist of a maximum 12-week screening/Baseline period, followed by a 12-week blinded treatment period, a 30-day safety follow-up, and a long-term follow-up period through Week 96 (approximately 2 years after randomization).

03

Conditions studied

  • Atherosclerosis
  • Coronary Artery Disease

Keywords

  • Plaque regression
  • Plaque stabilization
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Fully understands the purposes, features, and methods of the study and the possible adverse reactions, and is voluntarily willing to participate in the study, and signs the form (ICF) before performing any study-specific assessment.
  2. Male or female participants between 18 and 80 years (inclusive, at the time of signing the ICF).
  3. Participants must satisfy either of the following criteria:

1) Have clinically evident atherosclerotic CV disease (ASCVD) 2) Meet at least two of the following criteria at screening/baseline, as evidenced by:

  1. A history of Type 2 diabetes requiring treatment with medication,
  2. Aged > 55 years (women) or > 50 years (men),
  3. 2 or more of the following atherosclerosis risk factors:

    • Current cigarette smoker
    • Hypertension
    • Estimated (eGFR) 45 to 60 ml/min/1.73m2

      4. Known coronary atherosclerosis as evidenced through coronary angiography or CCTA. The following criteria must be met on the core lab CCTA interpretation for the patient to be enrolled: at least one epicardial coronary artery with a lumen stenosis of 25% to 69%, total coronary NCPV is at least 75 mm3, Detectable low-attenuation composition in one or more individual plaques.

      5. Female participants must be non-pregnant and non-lactating

      6. Willing and able to comply with the requirements of protocol to the best of the participant's and investigator's knowledge.

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with other drug(s) within 30 days or 5 half-lives, whichever is longer, prior to randomization.
  2. Previously received YN001.
  3. Any type of vaccination within 4 weeks prior to randomization, or any planned vaccination during the study treatment period
  4. for CCTA
  5. 3 major epicardial coronary arteries with ≥ 70% or left main ≥50% stenosis.
  6. Acute MI that occurred within 4 weeks prior to randomization.
  7. PCI performed within 2 weeks prior to randomization or PCI is required or planned during study treatment based on clinical indication for revascularization.
  8. Clinically evident stroke or (TIA) within 6 months prior to randomization.
  9. Relapse and highly symptomatic arrhythmia uncontrolled by drugs within the past 3 months.
  10. Prior coronary artery bypass graft (CABG), aortic root surgery with coronary reimplantation, left ventricular assist device (LVAD) placement, surgical aortic valve replacement (SAVR), transcatheter aortic valve replacement (TAVR), or heart transplantation, or a plan to undergo these procedures (CABG, aortic root surgery with coronary reimplantation, LVAD placement, SAVR, TAVR, or heart transplantation) during the study.
  11. class III or IV or last known (LVEF) was \<40%.
  12. Carotid endarterectomy or stenting, peripheral arterial revascularization, or abdominal aortic aneurysm repair within 4 weeks prior to randomization.
  13. History of myopathy or myositis, or susceptibility to myopathy/rhabdomyolysis (e.g., family history of hereditary myopathy, etc.).
  14. History of severe myalgia attributed to statin therapy or other significant concern about statin side effects.
  15. Known gastrointestinal ulcers, inflammatory bowel disease, or gastrointestinal/rectal bleeding within 6 months prior to randomization.
  16. Evidence of unresolved major diseases 2 weeks prior to randomization or planned major surgery during the study that, in the investigator's judgement, may interfere with the investigational product administration or trial assessments.
  17. Presenting with history of (except in participants who have been disease-free >5 years; or whose only malignancy has been basal or squamous cell skin carcinoma).
  18. Presence of any type of disease.
  19. Allergy to multiple foods or drugs or known sensitivity to any components to be administered during dosing.
  20. is less than 1 year.
  21. Systolic blood pressure of ≥ 160 mmHg at final screening despite antihypertensive therapy.
  22. Triglycerides ≥ 400 mg/dL (4.5 mmol/L) at final screening.
  23. LDL-C > 100 mg/dL (2.6 mmol/L) at final screening.
  24. Active liver disease or hepatic dysfunction defined by any of (ALT), aspartate aminotransferase (AST), > 3 times (ULN), or total > 2 times ULN at final screening.
  25. Presence of renal dysfunction, defined by \< 45 ml/min/1.73m2.
  26. Untreated or inadequately treated hypothyroidism.
  27. Poorly controlled Type 2 diabetes mellitus.
  28. A positive surface antigen (HBsAg), or positive antibody against virus (anti-HCV) or (anti-HIV), or positive treponema pallidum antibody (TP-Ab).
  29. Presence of any other diseases or conditions (apart from those outlined above) that, in the opinion of the investigator, would make it unsuitable for the participant to participate in this study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
456 participants (estimated)

Study arms

  • Experimental
    Dose 1 YN001/Placebo 40mg

    Dose 1 YN001/Placobo 40mg will be administrated intravenously weekly

    Drug: YN001/Placebo 40mg

  • Experimental
    Dose 2 YN001/Placebo 20mg

    Dose 2 YN001/Placebo 20mg will be administrated intravenously weekly

    Drug: YN001/Placebo 20mg

  • Placebo comparator
    Dose 3 YN001/Placebo 0mg

    Dose 3 YN001/Placebo 0mg will be administrated intravenously weekly

    Drug: YN001/Placebo 0mg

Interventions

  • DrugYN001/Placebo 40mg

    Dose 1 YN001/Placebo 40mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

  • DrugYN001/Placebo 20mg

    YN001/Placebo 20mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

  • DrugYN001/Placebo 0mg

    YN001/Placebo 0mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

06

What researchers measure

Primary outcomes

  1. Relative change from baseline in coronary NCPV at Week 13

    Relative change in coronary NCPV from baseline to Week 13 as determined by coronary computed tomography angiography (CCTA)

    Time frame: Baseline to Week 13

Secondary outcomes

  1. Absolute change from baseline in carotid intima-media thickness (IMT) at Week 13

    Absolute change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound.

    Time frame: From baseline to Week 13

  2. Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9

    Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9

    Time frame: From baseline to Week 9

  3. Relative change from baseline in carotid intima-media thickness (IMT) at Week 13

    Relative change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound

    Time frame: From baseline to Week 13

  4. Relative change in the maximum thickness and area of carotid plaque at Week 9, and Week 13

    Relative change in the maximum thickness and area of carotid plaque from baseline to Week 9, and Week 13 as determined by carotid ultrasound

    Time frame: From baseline to Week 9 and Week 13

  5. Relative change in coronary Percent Atheroma Volume (PAV) at Week 13

    Relative change in coronary Percent Atheroma Volume (PAV) from baseline to Week 13 as determined by CCTA

    Time frame: From baseline to Week 13

  6. Relative change in coronary Low Attenuation Plaque Volume(LAPV) at Week 13

    Relative change in coronary LAPV from baseline to Week 13 as determined by CCTA.

    Time frame: From baseline to week 13

  7. Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline at 48 week

    Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline to Week 48 as determined by CCTA

    Time frame: From baseline to week 48

  8. Absolute change in coronary NCPV at week 13 and week 48

    Absolute change in coronary NCPV from baseline to Week 13 and Week 48 as determined by CCTA

    Time frame: From baseline to week 13 and week 48

  9. Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)

    Time to the first occurrence of the MACE, composite of CV death, myocardial infarction (MI), ischemic stroke, urgent coronary revascularization, or hospitalization for unstable angina

    Time frame: From randomization to Week 96

  10. The safety profile of YN001

    Incidence of treatment emergent adverse event (TEAE)/serious adverse event (SAE)/adverse event of special interest (AESI)

    Time frame: From baseline to Week 13

  11. Immunogenicity (ADA) analysis

    Incidence of anti-drug antibodies (ADA) formation

    Time frame: From baseline to Week 13

  12. Immunogenicity (APA) analysis

    Incidence of anti-PEG antibodies (APA) formation

    Time frame: From baseline to Week 17

  13. YN001 concentrations analysis in plasma

    Sparse blood samples will be collected, and these concentrations are intended to be pooled with other studies to develop/update pharmacometric models

    Time frame: From baseline to Week 13

07

Study locations

35 of 56 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2027, 12 months after the start.

Of 46 phase 2 interventional studies under Atherosclerosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2026
First posted
Apr 9, 2026
StartActual
Jul 31, 2026
Primary completionEst.
Jul 31, 2027
CompletionEst.
Mar 31, 2029
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
14 sites changed recruiting status (14 now recruiting)
Show 14 sites
  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center · Torrance, United StatesNot yet recruiting→Recruiting
  • HCA Florida Heart Institute · St. Petersburg, United StatesNot yet recruiting→Recruiting
  • Midwest Heart & Vascular Specialists, LLC · Overland Park, United StatesNot yet recruiting→Recruiting
  • Capital Area Research, LLC - Camp Hill · Camp Hill, United StatesNot yet recruiting→Recruiting
  • Heart Center Research, LLC · Huntsville, United StatesNot yet recruiting→Recruiting
  • New Generation of Medical Research, LLC. · Hialeah, United StatesNot yet recruiting→Recruiting
  • PharmaTex Research, LLC · Amarillo, United StatesNot yet recruiting→Recruiting
  • Guangdong Provincial People's Hospital · Guangzhou, ChinaNot yet recruiting→Recruiting
  • Daqing People's Hospital · Daqing, ChinaNot yet recruiting→Recruiting
  • The Second Xiangya Hospital fo Central South University · Changsha, ChinaNot yet recruiting→Recruiting
  • Sichuan Provincial People's Hospital · Chengdu, ChinaNot yet recruiting→Recruiting
  • Zhejiang Provincial People's Hospital · Hangzhou, ChinaNot yet recruiting→Recruiting
  • The First Affiliated Hospital of Soochow University · Suzhou, ChinaNot yet recruiting→Recruiting
  • The 2nd Affiliated Hospital and Yuying Children's Hospital of WMU · Wenzhou, ChinaNot yet recruiting→Recruiting
across 2 updates, Oct 27, 2026 – Nov 5, 2026
Show all 2 updates
  1. Nov 5, 2026
    10 sites changed recruiting status (10 now recruiting)
    Show 10 sites
    • Heart Center Research, LLC · Huntsville, United StatesNot yet recruiting→Recruiting
    • New Generation of Medical Research, LLC. · Hialeah, United StatesNot yet recruiting→Recruiting
    • PharmaTex Research, LLC · Amarillo, United StatesNot yet recruiting→Recruiting
    • Guangdong Provincial People's Hospital · Guangzhou, ChinaNot yet recruiting→Recruiting
    • Daqing People's Hospital · Daqing, ChinaNot yet recruiting→Recruiting
    • The Second Xiangya Hospital fo Central South University · Changsha, ChinaNot yet recruiting→Recruiting
    • Sichuan Provincial People's Hospital · Chengdu, ChinaNot yet recruiting→Recruiting
    • Zhejiang Provincial People's Hospital · Hangzhou, ChinaNot yet recruiting→Recruiting
    • The First Affiliated Hospital of Soochow University · Suzhou, ChinaNot yet recruiting→Recruiting
    • The 2nd Affiliated Hospital and Yuying Children's Hospital of WMU · Wenzhou, ChinaNot yet recruiting→Recruiting
  2. Oct 27, 2026
    4 sites changed recruiting status (4 now recruiting)
    Show 4 sites
    • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center · Torrance, United StatesNot yet recruiting→Recruiting
    • HCA Florida Heart Institute · St. Petersburg, United StatesNot yet recruiting→Recruiting
    • Midwest Heart & Vascular Specialists, LLC · Overland Park, United StatesNot yet recruiting→Recruiting
    • Capital Area Research, LLC - Camp Hill · Camp Hill, United StatesNot yet recruiting→Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07521007
Lead sponsor
Beijing Inno Medicine Co., Ltd.
Collaborators
The TIMI Study Group
Responsible party
Sponsor
First posted
Apr 9, 2026
Start date
Jul 31, 2026
Primary completion
Jul 31, 2027 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Nov 5, 2026

Study contacts

Jingmei Zhang, Master
Contact
zhangjingmei@innovmedicine.com
0086 010 82599080
Kaiqi Zong, Master
Contact
zongkaiqi@innovmedicine.com
0086 010 82599080
Ying Chen, PhD
study director · Beijing Inno Medicine Co., Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion